1. IL-33 Depletion in COVID-19 Lungs
- Author
-
Stanley J. Radio, Heather M. Strah, Kristina L. Bailey, Michael J. Duryee, John D. Dickinson, Ted R. Mikuls, Bryant R. England, Todd A. Wyatt, Amy Nelson, Jill A. Poole, Dawn M. Katafiasz, Daniel R. Anderson, Rohit Gaurav, Geoffrey M. Thiele, and Debra J. Romberger
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Myocytes, Smooth Muscle ,Critical Care and Intensive Care Medicine ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ,lung ,Pulmonary Disease, Chronic Obstructive ,Young Adult ,IL-33, Interleukin-33 ,proSP-C, prosurfactant protein C ,Research Letter ,Humans ,Vimentin ,IPF, idiopathic pulmonary fibrosis ,Medicine ,Aged ,Aged, 80 and over ,SARS-CoV-2 ,business.industry ,COVID-19 ,Endothelial Cells ,Fibroblasts ,Middle Aged ,AEC2, type II alveolar epithelial cells ,Interleukin-33 ,Pulmonary Surfactant-Associated Protein C ,Virology ,Idiopathic Pulmonary Fibrosis ,Interleukin 33 ,COPD, chronic obstructive pulmonary disease ,inflammation ,Alveolar Epithelial Cells ,Case-Control Studies ,SARS-CoV2 ,IL-33 ,Female ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021